The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail

Efluelda Tetra, suspension for injection in pre-filled syringe

Sanofi PasteurPA2131/015/001

Main Information

Trade NameEfluelda Tetra, suspension for injection in pre-filled syringe
Active SubstancesB/PHUKET/3073/2013 -LIKE STRAIN (B/PHUKET/3073/2013, WILD TYPE)
A/Darwin/9/2021 (H3N2) - like strain (A/Darwin/9/2021, IVR-228)
B/Austria/1359417/2021 - like strain (B/Michigan/01/2021, wild type)
A/Victoria/4897/2022 (H1N1)pdm09-like strain (A/Victoria/4897/2022, IVR-238
Dosage FormSuspension for injection in pre-filled syringe
Licence HolderSanofi Pasteur
Licence NumberPA2131/015/001

Group Information

ATC CodeJ07BB02 influenza, inactivated, split virus or surface antigen


License statusAuthorised
Licence Issued24/04/2020
Legal statusProduct subject to prescription which may not be renewed (A)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing StatusNot marketed


Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportNo document available
« Back